4.7 Article

Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls

期刊

NEUROLOGY
卷 73, 期 15, 页码 1186-1192

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181bacf1b

关键词

-

资金

  1. Academy of Finland [205954]
  2. Sigrid Juselius Foundation
  3. clinical grants (EVO) of Turku University Hospital
  4. Paivi and Sakari Sohlberg Foundation
  5. Niilo Huolma Fellowship
  6. Medical Faculty of the University of Turku
  7. Tekes-Finnish Funding Agency for Technology and Innovation
  8. Academy of Finland (AKA) [205954, 205954] Funding Source: Academy of Finland (AKA)

向作者/读者索取更多资源

Objective: In Alzheimer disease (AD), the accumulation pattern of beta-amyloid over time and its relationship with dementia severity are unclear. We investigated the brain uptake of the amyloid ligand C-11-labeled Pittsburgh compound B ([C-11]PIB) and volumetric brain changes over a 2-year follow-up in patients with AD and in aged healthy controls. Methods: Fourteen patients with AD (mean age 72 years, SD 6.6) and 13 healthy controls (mean age 68 years, SD 5.4) were examined at baseline and after 2 years (patients with AD: mean 2.0 years, SD 0.2; controls: mean 2.1 years, SD 0.6) with [C-11]PIB PET, MRI, and neuropsychological assessments. [C-11]PIB uptake was analyzed with a voxel-based statistical method (SPM), and quantitative data were obtained with automated region-of-interest analysis. MRI data were analyzed with voxel-wise tensor-based morphometry. Results: The [C-11]PIB uptake of the patients with AD did not increase significantly during follow-up when compared with that of the controls. MRI showed progressive brain volume change in the patients with AD, e. g., in the hippocampal region, temporal cortex, and precuneus (p < 0.05). The mean Mini-Mental State Examination score of the patients with AD declined from 24.3 (SD 3.1) at baseline to 21.6 (SD 3.9) at follow-up (p = 0.009). Cognitive decline was also evident in other neuropsychological test results. Baseline neocortical [C-11]PIB uptake ratios predicted subsequent volumetric brain changes in the controls (r = 0.725, p = 0.005). Conclusions: The results suggest no (or only little) increase in C-11-labeled Pittsburgh compound B ([C-11]PIB) uptake during 2 years of Alzheimer disease progression, despite advancing brain atrophy and declining cognitive performance. Nevertheless, changes in [C-11]PIB uptake during a longer follow-up cannot be excluded. High cortical [C-11]PIB uptake may predict ongoing brain atrophy in cognitively normal individuals. Neurology (R) 2009; 73: 1186-1192

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据